Antibodies targeting SIRP alpha and uses thereof
By developing high-affinity and specific antagonistic SIRPα antibodies, the problem of insufficient affinity and activity of existing antibodies in treating tumors is solved, the phagocytosis of tumor cells is enhanced, the toxicity to normal cells is reduced, and the therapeutic effect is improved. Security.
Patent Information
- Application Number
- CN202380034177.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-20
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-26
AI Technical Summary
The existing SIRPα blocking antibodies have problems with insufficient affinity and activity when treating tumors, and are toxic to normal cells, affecting efficacy and safety.
An antagonistic SIRPα antibody or antigen-binding portion thereof has been developed, with a specific binding SIRPα, high affinity and blocking activity, capable of cross-reacting with SIRPβ, but does not bind SIRPγ and mouse SIRPα, for enhancing macrophage pairs phagocytic activity of tumor cells.
It improves the binding affinity and blocking activity of SIRPα for humans and monkeys, reduces the toxicity to normal cells, enhances the phagocytosis of tumor cells, and improves the anti-tumor activity in the body.
Smart Images

Figure BDA0005084070310000121 
Figure BDA0005084070310000311 
Figure BDA0005084070310000312
Abstract
Citation Information
Patent Citations
Method for the production of non-immunogenic proteins
US20030153043A1
Cells of which genome is modified
US20040110704A1
Chemical linkers and conjugates thereof
US20060024317A1
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A
Osmotic drug delivery system
US4439196A
Cited By
SMCP polyclonal antibody as well as preparation method and application thereof
CN120943955A
